DIGAMI

AcronymDefinition
DIGAMIDiabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The DIGAMI 2 trial was planned and conducted to further investigate the possible effects on mortality and morbidity of an insulin-based management on diabetic patients with AMI.
Moreover, a post hoc analysis of DIGAMI 2 [41], adjusting for confounders such as glycemic control, did not show any significant difference in mortality among sulphonylureas, metformin, and insulin.
The most reasonable reason for the difference between DIGAMI 1 and 2 findings is that in DIGAMI 2, changes in glucose concentrations between control and insulin treatment groups were nonsignificant, despite the intent to obtain target-driven, strict glycemic control in patients assigned to the insulin-based groups in these trials.
The last ESC task force on diabetes and CV diseases developed in collaboration with EASD suggested, according to DIGAMI 1, that DM and AMI would benefit from glycemic control, in the case of a significant hyperglycemia (higher than 10 mmol/L or 180 mg/dL), with the target adapted to possible comorbidities as a class 2a recommendation.
Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year followup of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial.
(13.) Malmberg K, Ryden L, Wedel H, et al, for the DIGAMI 2 Investigators.
STUDY KEY Abbreviations of studies mentioned in this article ACCORD Action to Control Cardiovascular Risk in Diabetes study ADVANCE Action in Diabetes and Vascular Disease study DIGAMI 2 Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction study HEART2D Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes study NHANES National Health and Nutrition Examination Surveys ORIGIN Outcome Reduction With Initial Glargine Intervention trial STOP-NIDDM Study to Prevent Non-Insulin- Dependent Diabetes Mellitus trial VADT Veterans Affairs Diabetes Trial UKPDS United Kingdom Prospective Diabetes Study
Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarctions 2(DIGAMI 2) calismasinda ise ilk DIGAMI calismasinin aksine tip 2 DM'li hastalarda Ml sonrasi akut dOnemde uygulanan veya devam edilen insulin tedavisinin kon-vansiyonel yOntemler ile benzer seviyelerde glukoz kontrolu ile karsilastirildiginda sagkalim, nonfatal miyokardiyal reinfarkt ve inme sayisinda gruplar arasinda anlamli farkliliklar saptanmamistir (12).
Dolayisi ile, DIGAMI 2 calismasi, ilk DIGAMI calismasinin tip 2 DM'li hastalarda MI sonrasi akut dOnemde uygulanan veya devam edilen insulin tedavisinin konvansiyonel yOntemler ile benzer seviyelerde glukoz kontrolu ile karsilastirildiginda sagkalimi iyilestirdigi veya insuline dayali tedavinin nonfatal miyokardiyal reinfarkt veya inme sayisini azalttigi gOrusunu desteklememektedir.
(12.) Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al; DIGAMI 2 Investigators.
Malmberg et al., "Mannose-binding lectin genotype and phenotype in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial," Diabetes Care, vol.
(34.) Malmberg K, and the DIGAMI (Diabetes Mellitus InsulinGlucose Infusion in Acute Myocardial Infarction) Study Group.